Drugs / Retosiban
last change Sep 2019 re-read 2 minutes ago

Retosiban

also known as GSK221149 · GSK221149A

Small molecule targets OXTR via inhibition

Developed for
pregnancy disorder · obstetric disorder
Investigated by
GlaxoSmithKline · PPD Development, LP

Trials 10 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT02377414 Mar → Apr 2015 pregnancy disorder GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT01867996 Jun → Sep 2013 pregnancy disorder GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT01702376 Oct 2012 → Jan 2013 pregnancy disorder GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT01627587 Dec 2011 → Feb 2012 obstetric disorder GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00449709 Mar 2007 → ? pregnancy disorder, premature ejaculation GlaxoSmithKline Terminated No outcome recorded
Phase 1 NCT00457925 Oct 2006 → ? obstetric disorder GlaxoSmithKline Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00404768 Oct 2007 → Jul 2011 obstetric disorder GlaxoSmithKline Completed No outcome recorded
Phase 33 trials
Phase 3 NCT02377466 Feb 2016 → Jul 2017 pregnancy disorder GlaxoSmithKline Terminated No outcome recorded
Phase 3 NCT02292784 Jun 2015 → Sep 2019 pregnancy disorder GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT02292771 Mar 2015 → Aug 2017 pregnancy disorder GlaxoSmithKline Terminated No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as Retosiban ClinicalTrials.gov intervention name — accepted as the source's own label NCT02377466
5

NCT02377414

NCT01867996

NCT02292784

NCT02292771

NCT01702376

Known as GSK221149 “A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)” NCT01867996
2

NCT01627587

NCT00449709

Known as GSK221149A ClinicalTrials.gov intervention name — accepted as the source's own label NCT00457925
1

NCT00404768

Action Inhibit “block the effects of oxytocin” NCT00404768
1

“Oxytocin receptor antagonist” CHEMBL429736

Modality Small molecule “Retosiban is a small molecule oxytocin receptor antagonist” PMID 26138866 Jun 2015
Route Intravenous “given an intravenous infusion of GSK221149A” NCT00404768
Target OXTR “Oxytocin receptor antagonist” CHEMBL429736